GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Eluxadoline (VIBERZI)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Viberzi

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - Viberzi

Product / population
VIBERZI; severe-renal and ESRD wording excludes dialysis patients from the cited ESRD population.
Renal measure
Indexed eGFR in mL/min/1.73 m2.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

Use 75 mg twice daily for moderate or severe renal impairment, defined by eGFR below 60, and for ESRD below 15 in patients not yet receiving dialysis. Mild impairment does not require adjustment. The nondialysis ESRD finding is not a validated dialysis recommendation. Full gallbladder, pancreatic, hepatic and interaction restrictions must still be checked before using this regimen.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/viberzi-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

GlobalRPh RX List

GlobalRPh RX List - Viberzi

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults with IBS-D; the renal recommendation does not override contraindications in the full label.

Renal method: eGFR, mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Viberzi

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

VIBERZI; severe-renal and ESRD wording excludes dialysis patients from the cited ESRD population.

Renal method: Indexed eGFR in mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - ViberziGlobalRPh RX List - Viberzi
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/viberzi-drug/

Product and population scope

Adults with IBS-D; the renal recommendation does not override contraindications in the full label.

RDM33-SCOPE-eluxadoline-viberzi-C1 · Source section: Exact product identity and selected populationRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Viberzi

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults with IBS-D; the renal recommendation does not override contraindications in the full label.

Renal method: eGFR, mL/min/1.73 m2.
Source date: Revised June 2020
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For eGFR below 60 mL/min/1.73 m2, including end-stage renal disease not yet on dialysis, the recommended dose is 75 mg twice daily with food. No adjustment is needed for mild impairment. The recommendation explicitly describes ESRD not yet on dialysis and must not be converted into a dialysis regimen.

RDM33-rxlist-eluxadoline-viberzi-C1 · Source locator: Dosage; use in specific populations: renal impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/viberzi-drug/
Retrieved
2026-09-07
Renal-function method
eGFR, mL/min/1.73 m2.
Source date/version
Revised June 2020
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
75ca0645498af9e5bcf55d16017cb9495c9667c898357f7e1704d9202dfc22cd
Rxlist

GlobalRPh RX List - Viberzi

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · VIBERZI; severe-renal and ESRD wording excludes dialysis patients from the cited ESRD population.

Renal method: Indexed eGFR in mL/min/1.73 m2.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Use 75 mg twice daily for moderate or severe renal impairment, defined by eGFR below 60, and for ESRD below 15 in patients not yet receiving dialysis. Mild impairment does not require adjustment. The nondialysis ESRD finding is not a validated dialysis recommendation. Full gallbladder, pancreatic, hepatic and interaction restrictions must still be checked before using this regimen.

RDM40-rxlist-eluxadoline-viberzi-df15711dda-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/viberzi-drug/
Retrieved
2026-09-07
Renal-function method
Indexed eGFR in mL/min/1.73 m2.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
f5fb16e52a8ea0ba5feca598038c7eb1588c5ee5d8d4d1e2ff215b19a5d476ae

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/viberzi-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
06efb8beb1119d77ac874f3300656e856913b23ab601d313d363b2a8680f0e60
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report